Early Minimal Residual Disease (MRD) Analysis During Treatment of Philadelphia Chromosome / Bcr -Abl Positive Acute Lymphoblastic Leukemia (Ph + ALL) with the Abl -Tyrosine Kinase Inhibitor STI571 (Glivec) Running title: MRD Analysis in Ph + ALL During STI571 T reatment